In Vitro Diagnostics (IVD) Market Size & Share Report, 2033
The global in vitro diagnostics (IVD) market size was valued at USD 78.19 billion in 2023 and is projected to surpass around USD 121.43 billion by 2033, registering a CAGR of 4.5% over the forecast period of 2024 to 2033.
-Market-Size-.webp "In Vitro Diagnostics (IVD) Market Size, 2024 to 2033")
The In Vitro Diagnostics (IVD) market encompasses a wide array of medical tests performed on samples such as blood, urine, and tissue in a laboratory setting. These tests are crucial for detecting diseases, monitoring health conditions, and guiding treatment decisions. The IVD market includes various product segments such as reagents, instruments, and software used in diagnostic procedures. Key players in the market include manufacturers of diagnostic equipment, laboratories, and healthcare providers. Rapid advancements in technology, such as the development of molecular diagnostics and point-of-care testing, continue to drive innovation in the IVD market. Additionally, the increasing prevalence of chronic and infectious diseases worldwide, coupled with the growing demand for personalized medicine, further contributes to the expansion of the IVD market. Furthermore, the COVID-19 pandemic has highlighted the importance of diagnostic testing, leading to accelerated growth and adoption of IVD solutions globally. Overall, the IVD market plays a critical role in modern healthcare by providing accurate and timely diagnostic information to healthcare professionals, ultimately improving patient outcomes.
| Report Attribute | Details |
| Market Size in 2024 | USD 81.71 Billion |
| Market Size by 2033 | USD 121.43 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 4.5% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Products, technology, application, end use, test location, region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Abbott; bioMérieux SA; QuidelOrtho Corp.; Siemens Healthineers AG; Bio-Rad Laboratories, Inc.; Qiagen; Sysmex Corp.; Charles River Laboratories; Quest Diagnostics Inc.; Agilent Technologies, Inc.; Danaher Corp.; BD; F. Hoffmann-La Roche Ltd. |
The growth can be attributed to increasing adoption of IVD owing to a rise in the incidence of infectious and chronic diseases. The development of automated IVD systems for laboratories and hospitals to provide efficient, accurate, and error-free diagnoses is expected to fuel market growth. The rising number of IVD products being launched by key players is also fueling market growth. For instance, in November 2023, ARUP Laboratories received a CE mark from EU-IVDR for AAV5 DetectCDx, a companion diagnostic to select the eligibility of severe hemophilia A-affected patients for BioMarin’s new gene therapy, Roctavian.
Technological advancements in terms of accuracy, portability, and cost-effectiveness are expected to be one of the high-impact rendering drivers of this market. Introduction of novel and highly accurate clinical laboratory tests is boosting the adoption of novel IVD tests worldwide. In June 2023, Toray Industries, Inc. received marketing approval from Japan’s Ministry of Health, Labour and Welfare for its Toray APOA2-iTQ used to diagnose pancreatic cancer. Moreover, in March 2023, Abbott received U.S. FDA clearance for its novel laboratory Traumatic Brain Injury (TBI) blood test in the U.S. Increasing approvals of IVD tests for life-threatening diseases are expected to create new opportunities in the untapped market.
Key players in the market undertake various strategies to strengthen their position and offer their customers diverse, technologically advanced & innovative products. New product launches and partnerships are the most prominently adopted by companies to attract more customers. For instance, in March 2023, BD received 510(k) clearance for BD Vaginal Panel on the BD COR System to detect infectious causes of vaginitis. In August 2023, the Precision Medicine Centre (PMC) formed a partnership with the Regional Molecular Diagnostic Service (RMDS) to implement genomic technology for the diagnosis of cancer in Northern Ireland.
Favorable initiatives undertaken by government and non-government bodies to improve overall healthcare services are anticipated to increase market growth. In October 2023, the WHO published the Essential Diagnostics List (EDL), a comprehensive list of IVD products that helps countries make decisions regarding diagnostic tools. It provides evidence-based recommendations and ensures the accessibility of essential products for target people. Moreover, in August 2023, the Africa CDC collaborated with the Africa Development Agency-New Partnership for Africa's Development (AUDA-NEPAD) to increase access to diagnostic tests across Africa. Such initiatives are expected to boost market growth.
A rise in the geriatric population and growth in knowledge regarding early testing have led to a surge in the number of regular check-ups, as a majority of deaths due to infections and chronic conditions occur in the population aged over 75 years. As per the Office for Budget Responsibility, UK, healthcare costs have risen exponentially, which can create economic pressure on nations with rapidly growing geriatric population. However, this expenditure is anticipated to translate positively for the IVD industry, driving market growth.
The reagents segment held the largest share of 65.92% of the overall revenue in 2023. The segment is expected to retain its dominance growing at the fastest CAGR from 2024 to 2030 owing to the extensive R&D initiatives undertaken by major players to develop novel reagents and test kits. For instance, in February 2023, BD received the market approval for the BD Onclarity HPV Assay to be used with the ThinPrep Pap Test in the U.S. The increasing R&D activities to enable faster cancer detection and precision medicine are allowing companies to focus on niche profitable areas in the IVD business. For instance, in March 2023, QIAGEN partnered with Servier to develop a companion diagnostic test for TIBSOVO, indicated for treating the blood cancer acute myeloid leukemia.
The growth in precision medicine is projected to enhance the overall demand for such novel reagents and consumables. The instruments segment held the second-largest share in 2023. Increasing approvals for novel IVD instruments are anticipated to drive segment growth. For instance, in April 2023, bioMérieux SA submitted 510(k) application to the U.S. FDA for VITEK REVEAL, rapid AST system. Players are aligning their instrument launches in line with the increasing genetic test requirement globally. For instance, in March 2022, Ion Torrent Genexus Dx Integrated Sequencer was introduced in the market by Thermo Fisher Scientific for research as well as diagnostic purposes.
The immunoassay segment accounted for the largest revenue share in 2023. Increasing incidence of chronic & communicable diseases and rising need for early diagnosis are among the key factors leading to an increase in demand for immunological methods, including different types of Enzyme-Linked Immunosorbent Assays (ELISAs). Moreover, key players are focused on R&D pertaining to development of new immunological diagnostic instruments and tests for IVD applications. For instance, in October 2023, Sysmex Corporation and Fujirebio Holdings, Inc. collaborated to enhance their R&D, production, clinical development, and marketing activities in immunoassay.
The coagulation segment is expected to grow at the fastest CAGR from 2024 to 2033. The segment can be attributed to the increasing prevalence of cardiovascular diseases, blood-related disorders, and autoimmune diseases. Moreover, instruments are getting updated and handheld coagulation analyzers, such as Xprecia stride coagulation analyzer, are anticipated to enhance the overall workflow of detection. Some of the key players offering instruments and coagulation tests are Abbott, Siemens Healthcare GmbH, and Beckman Coulter, Inc.
The hospitals segment held the largest revenue share in 2023 owing to a rise in the rate of hospitalizations that require support from faster diagnostics. Moreover, the ongoing development of healthcare infrastructure and favorable initiatives taken by government bodies are anticipated to enhance the existing hospital facilities. Thus, the demand for hospital-based IVD tests is increasing. Most IVD devices are purchased by hospitals and used in significant volumes. In 2023, there are over 6,129 hospitals in the U.S. that require constant aid from IVD for critical decision-making, as IVD tests provide faster and more accurate results.
In December 2023, the American Hospital Association wrote a letter to FDA not to apply device regulations on hospital’s LDTs. The homecare segment is expected to grow at a high CAGR from 2024 to 2033 due to the rising geriatric population and increasing demand for home care IVD devices. There is a growing need for novel molecular diagnostic and immunoassay platforms that can assist patients in conducting self-tests. For instance, in February 2023, the initial over-the-counter (OTC) home diagnostic test that can distinguish and identify influenza A and B, commonly referred to as the flu, and SARS-CoV-2, the virus causing COVID-19, was given an EUA by the FDA.
The others (lab-based tests) segment accounted for the largest revenue share in 2023. A large number of test analyses at one time and the higher accuracy of laboratory-based tests make them more reliable compared to PoC and home tests, giving segment a competitive edge over the other two segments. Moreover, the availability of tests that allow for sample collection at home and sending it to the laboratories for testing makes testing highly convenient for patients.
The homecare segment is expected to grow at a high CAGR from 2024 to 2033 due to the increasing reliability of these tests and patient-centric approaches of manufacturers. These tests have been an important source in mitigating the spread of the SARS-CoV-2. Significant actions have been taken by government bodies globally to ensure access to affordable and efficient homecare tests. In April 2023, Llusern Scientific, a University of South Wales spinoff, developed the PoC molecular diagnostic platform, Lodestar Dx platform, for panel testing of urinary tract infections.
The infectious diseases segment dominated the market in 2023. The outbreak of the COVID-19 pandemic increased the segment share significantly in recent years. Moreover, key players are introducing novel testing products to improve access to high-quality, innovative laboratory services for patients & healthcare providers. For instance, in February 2023, BD received EUA from the U.S. FDA for a new molecular diagnostic combination test for SARS-CoV-2, Influenza A+B, and Respiratory Syncytial Virus (RSV). Such initiatives by key players to strengthen their presence are expected to drive market growth.
The oncology segment is anticipated to grow at the fastest CAGR from 2024 to 2033. Increasing incidence of cancer coupled with a high mortality rate is increasing the demand for cancer biomarker tests at an early stage. Moreover, increasing approval of novel tests, R&D activities, and favorable initiatives undertaken by regulatory bodies are expected to drive industry growth. For instance, in June 2023, the U.S. FDA announced a pilot program that gives chance to manufacturers to submit validation and performance data for LDTs for cancer. Moreover, in April 2023, Biocartis Group NV & APIS Assay Technologies Ltd. collaborated to manufacture and commercialize a breast cancer subtyping test on Idylla, a molecular diagnostics platform.
North America dominated the market and accounted for a share of 42.39% in 2023. The region is estimated to retain its leading market position throughout the forecast period. The market in this region is collectively driven by factors, such as the rising incidence of chronic diseases, presence of strong players, increasing number of novel test launches, and supportive government funding. For instance, in January 2023, BD and CerTest Biotec received EUA from the U.S. FDA for a PCR test for Mpox virus detection in the U.S. Moreover, the increasing requirement for genetic testing for personalized health care, such as that for diabetes and cancer, is expected to drive market growth in North America.
Asia Pacific is anticipated to exhibit significant growth from 2024 to 2033. The regional market of Asia Pacific is expected to be driven by a number of factors, some of which include the presence of stabilizing economies, rapidly growing middle-class population, supportive government policies, and rapid urbanization across the region. For instance, in October 2023, Fapon and Halodoc partnered to increase the in vitro diagnostic product sales and services in Indonesia. Moreover, leading players are collaborating with regional players to expand their reach in developing countries in Asia Pacific.
Some of the key players operating in the in vitro diagnostics market include F. Hoffmann-La Roche Ltd.; Abbott; Quest Diagnostics Inc.; and Danaher. Market players are adopting various strategies, such as new product launches, mergers & acquisitions, and partnerships, to strengthen their product portfolios and offer diverse technologically advanced & innovative products.
Llusern Scientific, Biocartis Group NV, ARUP Laboratories, Veracyte, and Exact Sciences Corp are some of the emerging market participants in the market. Emerging companies are actively involved in developing novel and accurate IVD testing products to improve overall health services. Moreover, these companies are collaborating with research institutes, government bodies, and global leaders to increase the range of their products in potential markets.
In Vitro Diagnostics (IVD) Market Top Key Companies:
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the In Vitro Diagnostics (IVD) market.
By Product
By Technology
By Application
By Test Location
By End-use
By Region
Chapter 1 In Vitro Diagnostics Market: Methodology and Scope
1.1 Market Segmentation
1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 nova one advisor Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 Objectives
1.11.1 Objective 1
1.11.2 Objective 2
1.12 List Of Abbreviations
Chapter 2 In Vitro Diagnostics Market: Market Definitions
Chapter 3 In Vitro Diagnostics Market: Executive Summary
3.1 Market Summary
Chapter 4. In Vitro Diagnostics Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. In Vitro Diagnostics Market: Product Movement Analysis, USD Million, 2023 & 2030 (Volume Analysis)
4.3. Instruments
4.3.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) (Volume, Number of Instruments Sold)
4.4. Reagents
4.4.1. Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) (Volume, Number of Tests Sold)
4.5. Services
4.5.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. In Vitro Diagnostics Market: Technology Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. In Vitro Diagnostics Market: Technology Movement Analysis, USD Million, 2023 & 2030 (Volume Analysis)
5.3. Immunoassay
5.3.1. Immunoassay Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.2. Instruments
5.3.2.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.3. Reagents
5.3.3.1. Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.4. Services
5.3.4.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Hematology
5.4.1. Hematology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4.2. Instruments
5.4.2.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4.3. Reagents
5.4.3.1. Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4.4. Services
5.4.4.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Clinical Chemistry
5.5.1. Clinical Chemistry Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.2. Instruments
5.5.2.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.3. Reagents
5.5.3.1. Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.4. Services
5.5.4.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Molecular Diagnostics
5.6.1. Molecular Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6.2. Instruments
5.6.2.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6.3. Reagents
5.6.3.1. Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6.4. Services
5.6.4.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Coagulation
5.7.1. Coagulation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7.2. Instruments
5.7.2.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7.3. Reagents
5.7.3.1. Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7.4. Services
5.7.4.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. Microbiology
5.8.1. Microbiology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8.2. Instruments
5.8.2.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8.3. Reagents
5.8.3.1. Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8.4. Services
5.8.4.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.9. Others
5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.9.2. Instruments
5.9.2.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.9.3. Reagents
5.9.3.1. Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.9.4. Services
5.9.4.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. In Vitro Diagnostics Market: Application Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. In Vitro Diagnostics Market: Application Movement Analysis, USD Million, 2023 & 2030
6.3. Infectious Disease
6.3.1. Infectious Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Diabetes
6.4.1. Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Oncology/Cancer
6.5.1. Oncology/Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Cardiology
6.6.1. Cardiology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Nephrology
6.7.1. Nephrology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. Autoimmune Diseases
6.8.1. Autoimmune Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.9. Drug Testing
6.9.1. Drug Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.10. Others
6.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. In Vitro Diagnostics Market: Test Location Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. In Vitro Diagnostics Market: Test Location Movement Analysis, USD Million, 2023 & 2030
7.3. Point of Care
7.3.1. Point of Care Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Home-care
7.4.1. Home-care Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Others
7.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. In Vitro Diagnostics Market: End Use Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. In Vitro Diagnostics Market: End Use Movement Analysis, USD Million, 2023 & 2030
8.3. Hospitals
8.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4. Laboratory
8.4.1. Laboratory Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. Home-care
8.5.1. Home-care Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6. Others
8.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 9. In Vitro Diagnostics Market: Regional Estimates & Trend Analysis
9.1. In Vitro Diagnostics Market Share, By Region, 2023 & 2030, USD Million
9.2. North America
9.2.1. North America In Vitro Diagnostics Market Estimates and Forecasts, 2021 - 2033
9.2.2. U.S.
9.2.2.1. Key Country Dynamics
9.2.2.2. Regulatory Landscape/Reimbursement Scenario
9.2.2.3. Competitive Insights
9.2.2.4. U.S. In Vitro Diagnostics Market Estimates and Forecasts, 2021 - 2033
9.2.3. Canada
9.2.3.1. Key Country Dynamics
9.2.3.2. Regulatory Landscape/Reimbursement Scenario
9.2.3.3. Competitive Insights
9.2.3.4. Canada In Vitro Diagnostics Market Estimates and Forecasts, 2021 - 2033
9.3. Europe
9.3.1. Europe In Vitro Diagnostics Market Estimates and Forecasts, 2021 - 2033
9.3.2. UK
9.3.2.1. Key Country Dynamics
9.3.2.2. Regulatory Landscape/Reimbursement Scenario
9.3.2.3. Competitive Insights
9.3.2.4. U.K. In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.3.3. Germany
9.3.3.1. Key Country Dynamics
9.3.3.2. Regulatory Landscape/Reimbursement Scenario
9.3.3.3. Competitive Insights
9.3.3.4. Germany In Vitro Diagnostics Market Estimates and Forecasts, 2021 - 2033
9.3.4. France
9.3.4.1. Key Country Dynamics
9.3.4.2. Regulatory Landscape/Reimbursement Scenario
9.3.4.3. Competitive Insights
9.3.4.4. France In Vitro Diagnostics Market Estimates and Forecasts, 2021 - 2033
9.3.5. Italy
9.3.5.1. Key Country Dynamics
9.3.5.2. Regulatory Landscape/Reimbursement Scenario
9.3.5.3. Competitive Insights
9.3.5.4. Italy In Vitro Diagnostics Market Estimates and Forecasts, 2021 - 2033
9.3.6. Spain
9.3.6.1. Key Country Dynamics
9.3.6.2. Regulatory Landscape/Reimbursement Scenario
9.3.6.3. Competitive Insights
9.3.6.4. Spain In Vitro Diagnostics Market Estimates and Forecasts, 2021 - 2033
9.3.7. Sweden
9.3.7.1. Key Country Dynamics
9.3.7.2. Regulatory Landscape/Reimbursement Scenario
9.3.7.3. Competitive Insights
9.3.7.4. Sweden In Vitro Diagnostics Market Estimates and Forecasts, 2021 - 2033
9.3.8. Denmark
9.3.8.1. Key Country Dynamics
9.3.8.2. Regulatory Landscape/Reimbursement Scenario
9.3.8.3. Competitive Insights
9.3.8.4. Denmark In Vitro Diagnostics Market Estimates and Forecasts, 2021 - 2033
9.3.9. Norway
9.3.9.1. Key Country Dynamics
9.3.9.2. Regulatory Landscape/Reimbursement Scenario
9.3.9.3. Competitive Insights
9.3.9.4. Norway In Vitro Diagnostics Market Estimates and Forecasts, 2021 - 2033
9.3.10. Russia
9.3.10.1. Key Country Dynamics
9.3.10.2. Regulatory Landscape/Reimbursement Scenario
9.3.10.3. Competitive Insights
9.3.10.4. Russis In Vitro Diagnostics Market Estimates and Forecasts, 2021 - 2033
9.4. Asia Pacific
9.4.1. Asia Pacific In Vitro Diagnostics Market Estimates and Forecasts, 2021 - 2033
9.4.2. China
9.4.2.1. Key Country Dynamics
9.4.2.2. Regulatory Landscape/Reimbursement Scenario
9.4.2.3. Competitive Insights
9.4.2.4. China In Vitro Diagnostics Market Estimates and Forecasts, 2021 - 2033 (Volume, Number of Instruments Sold) (Volume, Number of Tests Sold)
9.4.3. Japan
9.4.3.1. Key Country Dynamics
9.4.3.2. Regulatory Landscape/Reimbursement Scenario
9.4.3.3. Competitive Insights
9.4.3.4. Japan In Vitro Diagnostics Market Estimates and Forecasts, 2021 - 2033
9.4.4. India
9.4.4.1. Key Country Dynamics
9.4.4.2. Regulatory Landscape/Reimbursement Scenario
9.4.4.3. Competitive Insights
9.4.4.4. India In Vitro Diagnostics Market Estimates and Forecasts, 2021 - 2033
9.4.5. South Korea
9.4.5.1. Key Country Dynamics
9.4.5.2. Regulatory Landscape/Reimbursement Scenario
9.4.5.3. Competitive Insights
9.4.5.4. South Korea In Vitro Diagnostics Market Estimates and Forecasts, 2021 - 2033
9.4.6. Australia
9.4.6.1. Key Country Dynamics
9.4.6.2. Regulatory Landscape/Reimbursement Scenario
9.4.6.3. Competitive Insights
9.4.6.4. Australia In Vitro Diagnostics Market Estimates and Forecasts, 2021 - 2033
9.4.7. Thailand
9.4.7.1. Key Country Dynamics
9.4.7.2. Regulatory Landscape/Reimbursement Scenario
9.4.7.3. Competitive Insights
9.4.7.4. Thailand In Vitro Diagnostics Market Estimates and Forecasts, 2021 - 2033
9.4.8. Singapore
9.4.8.1. Key Country Dynamics
9.4.8.2. Regulatory Landscape/Reimbursement Scenario
9.4.8.3. Competitive Insights
9.4.8.4. Singapore In Vitro Diagnostics Market Estimates and Forecasts, 2021 - 2033
9.5. Latin America
9.5.1. Latin America In Vitro Diagnostics Market Estimates and Forecasts, 2021 - 2033
9.5.2. Brazil
9.5.2.1. Key Country Dynamics
9.5.2.2. Regulatory Landscape/Reimbursement Scenario
9.5.2.3. Competitive Insights
9.5.2.4. Brazil In Vitro Diagnostics Market Estimates and Forecasts, 2021 - 2033
9.5.3. Mexico
9.5.3.1. Key Country Dynamics
9.5.3.2. Regulatory Landscape/Reimbursement Scenario
9.5.3.3. Competitive Insights
9.5.3.4. Mexico In Vitro Diagnostics Market Estimates and Forecasts, 2021 - 2033
9.5.4. Argentina
9.5.4.1. Key Country Dynamics
9.5.4.2. Regulatory Landscape/Reimbursement Scenario
9.5.4.3. Competitive Insights
9.5.4.4. Argentina In Vitro Diagnostics Market Estimates and Forecasts, 2021 - 2033
9.6. Middle East and Africa
9.6.1. Middle East and Africa In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.2. Saudi Arabia
9.6.2.1. Key Country Dynamics
9.6.2.2. Regulatory Landscape/Reimbursement Scenario
9.6.2.3. Competitive Insights
9.6.2.4. Saudi Arabia In Vitro Diagnostics Market Estimates and Forecasts, 2021 - 2033
9.6.3. UAE
9.6.3.1. Key Country Dynamics
9.6.3.2. Regulatory Landscape/Reimbursement Scenario
9.6.3.3. Competitive Insights
9.6.3.4. UAE In Vitro Diagnostics Market Estimates and Forecasts, 2021 - 2033
9.6.4. South Africa
9.6.4.1. Key Country Dynamics
9.6.4.2. Regulatory Landscape/Reimbursement Scenario
9.6.4.3. Competitive Insights
9.6.4.4. South Africa In Vitro Diagnostics Market Estimates and Forecasts, 2021 - 2033
9.6.5. Kuwait
9.6.5.1. Key Country Dynamics
9.6.5.2. Regulatory Landscape/Reimbursement Scenario
9.6.5.3. Competitive Insights
9.6.5.4. Kuwait In Vitro Diagnostics Market Estimates and Forecasts, 2021 - 2033
Chapter 10. Competitive Landscape
10.1. Recent Developments & Impact Analysis by Key Market Participants
10.2. Company Categorization
10.3. Global Company Market Share Analysis, 2023
10.4. Company Heat Map Analysis
10.5. Strategy Mapping
10.5.1. Expansion
10.5.2. Mergers & Acquisition
10.5.3. Partnerships & Collaborations
10.5.4. New Product Launches
10.5.5. Research And Development
10.6. Company Profiles
10.6.1. QIAGEN
10.6.1.1. Participant’s Overview
10.6.1.2. Financial Performance
10.6.1.3. Product Benchmarking
10.6.1.4. Recent Developments
10.6.2. BD
10.6.2.1. Participant’s Overview
10.6.2.2. Financial Performance
10.6.2.3. Product Benchmarking
10.6.2.4. Recent Developments
10.6.3. bioMérieux SA
10.6.3.1. Participant’s Overview
10.6.3.2. Financial Performance
10.6.3.3. Product Benchmarking
10.6.3.4. Recent Developments
10.6.4. F. Hoffmann-La Roche, Ltd.
10.6.4.1. Participant’s Overview
10.6.4.2. Financial Performance
10.6.4.3. Product Benchmarking
10.6.4.4. Recent Developments
10.6.5. QuidelOrtho Corporation
10.6.5.1. Participant’s Overview
10.6.5.2. Financial Performance
10.6.5.3. Product Benchmarking
10.6.5.4. Recent Developments
10.6.6. Abbott
10.6.6.1. Participant’s Overview
10.6.6.2. Financial Performance
10.6.6.3. Product Benchmarking
10.6.6.4. Recent Developments
10.6.7. Agilent Technologies, Inc.
10.6.7.1. Participant’s Overview
10.6.7.2. Financial Performance
10.6.7.3. Product Benchmarking
10.6.7.4. Recent Developments
10.6.8. Siemens Healthineers AG
10.6.8.1. Participant’s Overview
10.6.8.2. Financial Performance
10.6.8.3. Product Benchmarking
10.6.8.4. Recent Developments
10.6.9. Bio-Rad Laboratories, Inc.
10.6.9.1. Participant’s Overview
10.6.9.2. Financial Performance
10.6.9.3. Product Benchmarking
10.6.9.4. Recent Developments
10.6.10. Danaher
10.6.10.1. Participant’s Overview
10.6.10.2. Financial Performance
10.6.10.3. Product Benchmarking
10.6.10.4. Recent Developments
10.6.11. Sysmex Corporation
10.6.11.1. Participant’s Overview
10.6.11.2. Financial Performance
10.6.11.3. Product Benchmarking
10.6.11.4. Recent Developments
10.6.12. Charles River Laboratories
10.6.12.1. Participant’s Overview
10.6.12.2. Financial Performance
10.6.12.3. Product Benchmarking
10.6.12.4. Recent Developments
10.6.13. Quest Diagnostics Incorporated
10.6.13.1. Participant’s Overview
10.6.13.2. Financial Performance
10.6.13.3. Product Benchmarking
10.6.13.4. Recent Developments
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers